These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 20167994)

  • 21. A combined-formulation tablet of lamivudine/nevirapine/stavudine: bioequivalence compared with concurrent administration of lamivudine, nevirapine, and stavudine in healthy Indian subjects.
    Narang VS; Lulla A; Malhotra G; Purandare S
    J Clin Pharmacol; 2005 Mar; 45(3):265-74. PubMed ID: 15703362
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A randomized crossover study to determine bioequivalence of generic and brand name nevirapine, zidovudine, and lamivudine in HIV-negative women in India.
    Vezina HE; Henry K; Ravindran GD; Kurpad AV; Raj TD; Fox K; Weller D; Brundage RC; Cavert W; Balfour HH
    J Acquir Immune Defic Syndr; 2006 Feb; 41(2):131-6. PubMed ID: 16394842
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Randomized, open-label, comparative trial to evaluate the efficacy and safety of three antiretroviral drug combinations including two nucleoside analogues and nevirapine for previously untreated HIV-1 Infection: the OzCombo 2 study.
    French M; Amin J; Roth N; Carr A; Law M; Emery S; Drummond F; Cooper D;
    HIV Clin Trials; 2002; 3(3):177-85. PubMed ID: 12032876
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nevirapine/lamivudine/stavudine as a combined-formulation tablet: bioequivalence study compared with each component administered concurrently under fasting condition.
    Monif T; Tippabhotla SK; Garg M; Singla AK; Vijan T
    Int J Clin Pharmacol Ther; 2006 Jun; 44(6):276-83. PubMed ID: 16800100
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics of nevirapine: once-daily versus twice-daily dosing in the 2NN study.
    Kappelhoff BS; Huitema AD; van Leth F; Robinson PA; MacGregor TR; Lange JM; Beijnen JH;
    HIV Clin Trials; 2005; 6(5):254-61. PubMed ID: 16306032
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics and acceptability of once- versus twice-daily lamivudine and abacavir in HIV type-1-infected Ugandan children in the ARROW Trial.
    Musiime V; Kendall L; Bakeera-Kitaka S; Snowden WB; Odongo F; Thomason M; Musoke P; Adkison K; Burger D; Mugyenyi P; Kekitiinwa A; Gibb DM; Walker AS;
    Antivir Ther; 2010; 15(8):1115-24. PubMed ID: 21149918
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and efficacy of a simplified fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-VIR) for the treatment of advanced HIV-infected patients: a 24-week study.
    Anekthananon T; Ratanasuwan W; Techasathit W; Sonjai A; Suwanagool S
    J Med Assoc Thai; 2004 Jul; 87(7):760-7. PubMed ID: 15521230
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A single-dose, randomized, open-label, two-period crossover bioequivalence study comparing a fixed-dose pediatric combination of lamivudine and stavudine tablet for oral suspension with individual liquid formulations in healthy adult male volunteers.
    Monif T; Reyar S; Tiwari HK; Tippabhotla SK; Khuroo A; Thudi NR; Ahmed S; Raghuvanshi R
    Arzneimittelforschung; 2009; 59(2):104-8. PubMed ID: 19338141
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Strategies for nevirapine initiation in HIV-infected children taking pediatric fixed-dose combination "baby pills" in Zambia: a randomized controlled trial.
    Mulenga V; Cook A; Walker AS; Kabamba D; Chijoka C; Ferrier A; Kalengo C; Kityo C; Kankasa C; Burger D; Thomason M; Chintu C; Gibb DM
    Clin Infect Dis; 2010 Nov; 51(9):1081-9. PubMed ID: 20868279
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Experience with the use of a first-line regimen of stavudine, lamivudine and nevirapine in patients in the TREAT Asia HIV Observational Database.
    Zhou J; Paton NI; Ditangco R; Chen YM; Kamarulzaman A; Kumarasamy N; Lee CK; Li PC; Merati TP; Phanuphak P; Pujari S; Vibhagool A; Zhang F; Chuah J; Frost KR; Cooper DA; Law MG
    HIV Med; 2007 Jan; 8(1):8-16. PubMed ID: 17305926
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics of nevirapine in HIV-infected children under 3 years on rifampicin-based antituberculosis treatment.
    Oudijk JM; McIlleron H; Mulenga V; Chintu C; Merry C; Walker AS; Cook A; Gibb DM; Burger DM
    AIDS; 2012 Jul; 26(12):1523-8. PubMed ID: 22546991
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Drug resistance in human immunodeficiency virus type-1 infected Zambian children using adult fixed dose combination stavudine, lamivudine, and nevirapine.
    Gupta RK; Ford D; Mulenga V; Walker AS; Kabamba D; Kalumbi M; Grant PR; Ferrier A; Pillay D; Gibb DM; Chintu C
    Pediatr Infect Dis J; 2010 Aug; 29(8):e57-62. PubMed ID: 20508547
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trial.
    Laurent C; Kouanfack C; Koulla-Shiro S; Nkoué N; Bourgeois A; Calmy A; Lactuock B; Nzeusseu V; Mougnutou R; Peytavin G; Liégeois F; Nerrienet E; Tardy M; Peeters M; Andrieux-Meyer I; Zekeng L; Kazatchkine M; Mpoudi-Ngolé E; Delaporte E
    Lancet; 2004 Jul 3-9; 364(9428):29-34. PubMed ID: 15234853
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Plasma nevirapine levels and 24-week efficacy of a fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-VIR) among Thai HIV-infected patients.
    Manosuthi W; Kiertiburanakul S; Chaovavanich A; Sungkanuparph S
    J Med Assoc Thai; 2007 Feb; 90(2):244-50. PubMed ID: 17375627
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetic characteristics of ritonavir, zidovudine, lamivudine, and stavudine in children with human immunodeficiency virus infection.
    Fletcher CV; Yogev R; Nachman SA; Wiznia A; Pelton S; McIntosh K; Stanley K
    Pharmacotherapy; 2004 Apr; 24(4):453-9. PubMed ID: 15098798
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discontinuation of standard first-line antiretroviral therapy in a cohort of 1434 Malawian children.
    Buck WC; Kabue MM; Kazembe PN; Kline MW
    J Int AIDS Soc; 2010 Aug; 13():31. PubMed ID: 20691049
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Management of HIV-1 infection with a combination of nevirapine, stavudine, and lamivudine: a preliminary report on the Nigerian antiretroviral program.
    Idigbe EO; Adewole TA; Eisen G; Kanki P; Odunukwe NN; Onwujekwe DI; Audu RA; Araoyinbo ID; Onyewuche JI; Salu OB; Adedoyin JA; Musa AZ
    J Acquir Immune Defic Syndr; 2005 Sep; 40(1):65-9. PubMed ID: 16123684
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy, tolerability and pharmacokinetics of two nelfinavir-based regimens in human immunodeficiency virus-infected children and adolescents: pediatric AIDS clinical trials group protocol 403.
    King JR; Nachman S; Yogev R; Hodge J; Aldrovandi G; Hughes MD; Chen J; Wiznia A; Damle B; Acosta EP
    Pediatr Infect Dis J; 2005 Oct; 24(10):880-5. PubMed ID: 16220085
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetic evaluation and short-term activity of stavudine, nevirapine, and nelfinavir therapy in HIV-1-infected adults.
    Skowron G; Leoung G; Hall DB; Robinson P; Lewis R; Grosso R; Jacobs M; Kerr B; MacGregor T; Stevens M; Fisher A; Odgen R; Yen-Lieberman B
    J Acquir Immune Defic Syndr; 2004 Apr; 35(4):351-8. PubMed ID: 15097151
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics of lamivudine & stavudine in generic fixed-dose combinations in HIV-1 infected adults in India.
    Hemanth Kumar AK; Ramachandran G; Rajasekaran S; Padmapriyadarsini C; Narendran G; Anitha S; Subramanyam S; Kumaraswami V; Swaminathan S
    Indian J Med Res; 2009 Oct; 130(4):451-7. PubMed ID: 19942751
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.